A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly)
Latest Information Update: 29 Jan 2021
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Granulocyte colony-stimulating factors; Prednisone; Vincristine
- Indications Anaplastic large cell lymphoma; Carcinoma; Extranodal NK-T-cell lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- Acronyms A-CHOP-14; HOVON 91 T-NHL / ACT-2
- 01 Jan 2021 Primary endpoint has not been met. (Event free survival)
- 01 Jan 2021 Results published in the Leukemia
- 04 Dec 2018 Results (n=252) of pooled analysis of ACT-1 and ACT-2 comparing CHOP with A-CHOP to increase statistical power, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.